Gut commensal Bacteroides faecichinchillae, a potential novel candidate of next-generation probiotics targeting type 2 diabetes
于Beneficial MicrobesSearch for other papers by M. Godet in
Current site
Google Scholar
Search for other papers by E. Delmas in
Current site
Google Scholar
Search for other papers by C. Gérard in
Current site
Google Scholar
Search for other papers by E. Meugnier in
Current site
Google Scholar
Search for other papers by A. Bravard in
Current site
Google Scholar
Search for other papers by C. Pinteur in
Current site
Google Scholar
Search for other papers by N. Vega in
Current site
Google Scholar
Search for other papers by N. Bendridi in
Current site
Google Scholar
Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France
Search for other papers by D. Cheillan in
Current site
Google Scholar
Search for other papers by S. Fourati in
Current site
Google Scholar
Search for other papers by D. Rainteau in
Current site
Google Scholar
Search for other papers by M. Le Barz in
Current site
Google Scholar
Search for other papers by S. Binda in
Current site
Google Scholar
Search for other papers by F. Leulier in
Current site
Google Scholar
Search for other papers by A. Bernalier-Donadille in
Current site
Google Scholar
Search for other papers by H. Vidal in
Current site
Google Scholar
Abstract
The implication of gut microbiota in the pathophysiology of type 2 diabetes, one of the major health concerns worldwide, has demonstrated the benefits of using probiotics to improve dysbiosis. Facing the lack of defined research strategy to found and qualify bacterial with real antidiabetic activity, we have developed a program to identify, select and validate novel strains able to improve metabolic alterations in type 2 diabetes. Among potential candidates, we identified Bacteroides faecichinchillae (named BAfa hereafter), and the present work presents the validation of the antidiabetic potential of the ST37 (DSMZ 26883) BAfa strain in mice fed a high-fat high-sucrose (HFS) diet for 10 weeks followed by 4 weeks of treatment. Daily gavage with live, but not heat inactivated, BAfa improved glucose tolerance, fasting hyperinsulinemia and liver triglyceride content in HFS fed mice. Furthermore, these beneficial effects were retained after lyophilization. Using this preclinical model, we characterised BAfa mechanism of action, showing that four weeks of treatment was associated with reduced hepatic accumulation of ceramides, key actors of insulin resistance. The underlying mechanism could be related to BAfa-induced changes in the intestinal bile acid profile and inhibition of the Fxr-Fgf15 pathway in the ileum. BAfa supplementation during 4 weeks in HFS fed mice was also associated with mild modifications of gut microbiota composition, with the upregulation of several species known for their beneficial metabolic actions (such as Lactobacillus johnsonii, Limosilactobacillus reutei, Roseburia, Turicimonas muris, Phocaeicola dorei or Akkermansia muciniphila) and for being up-regulated during metformin treatment. Altogether, these data indicate that BAfa and related B. faecichinchillae strains could be considered for developing next-generation probiotics to treat type 2 diabetes, potentially in combination with the anti-diabetic drug metformin.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Beau, A., Benoit, B., Le Barz, M., Meugnier, E., Penhoat, A., Calzada, C., Pinteur, C., Loizon, E., Chanon, S., Vieille-Marchiset, A., Sauvinet, V., Godet, M., Laugerette, F., Holowacz, S., Jacouton, E., Michalski, M.-C. and Vidal, H., 2023. Inhibition of intestinal FXR activity as a possible mechanism for the beneficial effects of a probiotic mix supplementation on lipid metabolism alterations and weight gain in mice fed a high fat diet. Gut Microbes 15: 2281015. https://doi.org/10.1080/19490976.2023.2281015
-
Bravard, A., Gérard, C., Defois, C., Benoit, B., Makki, K., Meugnier, E., Rainteau, D., Rieusset, J., Godet, M. and Vidal, H., 2021. Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice. Science Reports 11: 16684. https://doi.org/10.1038/s41598-021-95117-0
-
Brown, E.M., Ke, X., Hitchcock, D., Jeanfavre, S., Avila-Pacheco, J., Nakata, T., Arthur, T.D., Fornelos, N., Heim, C., Franzosa, E.A., Watson, N., Huttenhower, C., Haiser, H.J., Dillow, G., Graham, D.B., Finlay, B.B., Kostic, A.D., Porter, J.A., Vlamakis, H., Clish, C.B. and Xavier, R.J., 2019. Bacteroides-derived sphingolipids are critical for maintaining intestinal homeostasis and symbiosis. Cell Host and Microbe 25: 668-680.e7. https://doi.org/10.1016/j.chom.2019.04.002
-
Clement, K., LeRoy, T., Debadat, J. and Voland, L., 2022. Composition and use of Turicimonas muris for the treatment of metabolic diseases. PCT/FR2022/052482.
-
Da Costa, W.K.A., Brandão, L.R., Martino, M.E., Garcia, E.F., Alves, A.F., de Souza, E.L., de Souza Aquino, J., Saarela, M., Leulier, F., Vidal, H. and Magnani, M., 2019. Qualification of tropical fruit-derived Lactobacillus plantarum strains as potential probiotics acting on blood glucose and total cholesterol levels in Wistar rats. Food Research International 124: 109-117. https://doi.org/10.1016/j.foodres.2018.08.035
-
de Carvalho, M.B., Jorge, G.M.C.P., Zanardo, L.W., Hamada, L.M., Izabel, L. dos S., Santoro, S. and Magdalon, J., 2024. The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials. American Journal of Physiology – Endocrinology and Metabolism 327: E279-E289. https://doi.org/10.1152/ajpendo.00156.2024
-
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N.M., de Barsy, M., Loumaye, A., Hermans, M.P., Thissen, J.-P., de Vos, W.M. and Cani, P.D., 2019. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine 25: 1096-1103. https://doi.org/10.1038/s41591-019-0495-2
-
Garcı́a-López, M., Meier-Kolthoff, J.P., Tindall, B.J., Gronow, S., Woyke, T., Kyrpides, N.C., Hahnke, R.L. and Göker, M., 2019. Analysis of 1,000 type-strain genomes improves taxonomic classification of Bacteroidetes. Frontiers in Microbiology 10: 2083. https://doi.org/10.3389/fmicb.2019.02083
-
Global status report on noncommunicable diseases, 2014. World Health Organization WHO/NMH/NVI/15.1
-
Godet, M., Meugnier, E., Vitalis, O., Bendridi, N., Vieille-Marchiset, A., Vega, N., Benoit, B., Pinteur, C., Rainteau, D., Cheillan, D., Michalski, M.-C., Chikh, K. and Vidal, H., 2025. Evaluation of the effects of metformin on gut functions and microbiota and their contribution to improving glucose tolerance in diabetic mice. Molecular Metabolism 102: 102263. https://doi.org/10.1016/j.molmet.2025.102263
-
Hsieh, F.-C., Lee, C.-L., Chai, C.-Y., Chen, W.-T., Lu, Y.-C. and Wu, C.-S., 2013. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutrition and Metabolism 10: 35. https://doi.org/10.1186/1743-7075-10-35
-
Humbert, L., Maubert, M.A., Wolf, C., Duboc, H., Mahé, M., Farabos, D., Seksik, P., Mallet, J.M., Trugnan, G., Masliah, J. and Rainteau, D., 2012. Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients. Journal of Chromatography B 899: 135-145. https://doi.org/10.1016/j.jchromb.2012.05.015
-
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K.W., Shi, J., Brocker, C.N., Desai, D., Amin, S.G., Bisson, W.H., Liu, Y., Gavrilova, O., Patterson, A.D. and Gonzalez, F.J., 2015. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nature Communications 6: 10166. https://doi.org/10.1038/ncomms10166
-
Johnson, E.L., Heaver, S.L., Waters, J.L., Kim, B.I., Bretin, A., Goodman, A.L., Gewirtz, A.T., Worgall, T.S. and Ley, R.E., 2020. Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. Nature Communications 11: 2471. https://doi.org/10.1038/s41467-020-16274-w
-
Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., Tameda, M., Shiraki, K., Ito, M., Takei, Y. and Takase, K., 2015. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterology 15: 100. https://doi.org/10.1186/s12876-015-0330-2
-
Kitahara, M., Sakamoto, M., Tsuchida, S., Kawasumi, K., Amao, H., Benno, Y. and Ohkuma, M., 2012. Bacteroides stercorirosoris sp. nov. and Bacteroides faecichinchillae sp. nov., isolated from chinchilla (Chinchilla lanigera) faeces. International Journal of Systematic and Evolutionary Microbiology 62: 1145-1150. https://doi.org/10.1099/ijs.0.032706-0
-
Le Barz, M., Vors, C., Combe, E., Joumard-Cubizolles, L., Lecomte, M., Joffre, F., Trauchessec, M., Pesenti, S., Loizon, E., Breyton, A.-E., Meugnier, E., Bertrand, K., Drai, J., Robert, C., Durand, A., Cuerq, C., Gaborit, P., Leconte, N., Bernalier-Donadille, A., Cotte, E., Laville, M., Lambert-Porcheron, S., Ouchchane, L., Vidal, H., Malpuech-Brugère, C., Cheillan, D. and Michalski, M.-C., 2021. Milk polar lipids favorably alter circulating and intestinal ceramide and sphingomyelin species in postmenopausal women. JCI Insight 6: e146161. https://doi.org/10.1172/jci.insight.146161
-
Lee, H., An, J., Kim, J., Choi, D., Song, Y., Lee, C.-K., Kong, H., Kim, S.B. and Kim, K., 2022. A novel bacterium, Butyricimonas virosa, preventing HFD-induced diabetes and metabolic disorders in mice via GLP-1 receptor. Frontiers in Microbiology 13: 858192. https://doi.org/10.3389/fmicb.2022.858192
-
Natividad, J.M., Agus, A., Planchais, J., Lamas, B., Jarry, A.C., Martin, R., Michel, M.-L., Chong-Nguyen, C., Roussel, R., Straube, M., Jegou, S., McQuitty, C., Le Gall, M., Da Costa, G., Lecornet, E., Michaudel, C., Modoux, M., Glodt, J., Bridonneau, C., Sovran, B., Dupraz, L., Bado, A., Richard, M.L., Langella, P., Hansel, B., Launay, J.-M., Xavier, R.J., Duboc, H. and Sokol, H., 2018. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metabolism 28: 737-749.e4. https://doi.org/10.1016/j.cmet.2018.07.001
-
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., Myridakis, A., Delzenne, N.M., Klievink, J., Bhattacharjee, A., van der Ark, K.C.H., Aalvink, S., Martinez, L.O., Dumas, M.-E., Maiter, D., Loumaye, A., Hermans, M.P., Thissen, J.-P., Belzer, C., de Vos, W.M. and Cani, P.D., 2017. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine 23: 107-113. https://doi.org/10.1038/nm.4236
-
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., Peng, Y., Zhang, D., Jie, Z., Wu, W., Qin, Y., Xue, W., Li, J., Han, L., Lu, D., Wu, P., Dai, Y., Sun, X., Li, Z., Tang, A., Zhong, S., Li, X., Chen, W., Xu, R., Wang, M., Feng, Q., Gong, M., Yu, J., Zhang, Y., Zhang, M., Hansen, T., Sanchez, G., Raes, J., Falony, G., Okuda, S., Almeida, M., LeChatelier, E., Renault, P., Pons, N., Batto, J.-M., Zhang, Z., Chen, H., Yang, R., Zheng, W., Li, S., Yang, H., Wang, J., Ehrlich, S.D., Nielsen, R., Pedersen, O., Kristiansen, K. and Wang, J., 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60. https://doi.org/10.1038/nature11450
-
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., Zhang, S., Yun, C., Lian, G., Zhang, X., Zhang, H., Bisson, W.H., Shi, J., Gao, X., Ge, P., Liu, C., Krausz, K.W., Nichols, R.G., Cai, J., Rimal, B., Patterson, A.D., Wang, X., Gonzalez, F.J. and Jiang, C., 2018. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nature Medicine 24: 1919-1929. https://doi.org/10.1038/s41591-018-0222-4
-
Wu, F., Guo, Y., Wang, Y., Sui, X., Wang, H., Zhang, H., Xin, B., Yang, C., Zhang, C., Jiang, S., Qu, L., Feng, Q., Dai, Z., Shi, C. and Li, Y., 2024. Effects of long-term fasting on gut microbiota, serum metabolome, and their association in male adults. Nutrients 17: 35. https://doi.org/10.3390/nu17010035
-
Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L.M., Serino, M., Planas-Fèlix, M., Xifra, G., Mercader, J.M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernàndez-Real, J.M. and Bäckhed, F., 2017. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine 23: 850-858. https://doi.org/10.1038/nm.4345
-
Xie, C., Jiang, C., Shi, J., Gao, X., Sun, D., Sun, L., Wang, T., Takahashi, S., Anitha, M., Krausz, K.W., Patterson, A.D. and Gonzalez, F.J., 2016. An intestinal farnesoid X receptor–ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66: 613-626. https://doi.org/10.2337/db16-0663
-
Xin, J., Zeng, D., Wang, H., Ni, X., Yi, D., Pan, K. and Jing, B., 2014. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Applied Microbiology and Biotechnology 98: 6817-6829. https://doi.org/10.1007/s00253-014-5752-1
-
Xu, X., Wang, Y., Wu, X., Cai, T., Dong, L., Liang, S., Zhu, L., Song, X., Dong, Y., Zheng, Y., Li, L. and Sun, W., 2024. Administration of Alistipes indistinctus prevented the progression from nonalcoholic fatty liver disease to nonalcoholic steatohepatitis by enhancing the gut barrier and increasing Lactobacillus spp. Biochemical and Biophysical Research Communications 741: 151033. https://doi.org/10.1016/j.bbrc.2024.151033
Supplementary Materials
| 全部期间 | 过去一年 | 过去30天 | |
|---|---|---|---|
| 摘要浏览次数 | 201 | 201 | 79 |
| 全文浏览次数 | 5 | 5 | 2 |
| PDF下载次数 | 15 | 15 | 6 |
Gut commensal Bacteroides faecichinchillae, a potential novel candidate of next-generation probiotics targeting type 2 diabetes
于Beneficial MicrobesSearch for other papers by M. Godet in
Current site
Google Scholar
PubMed
Search for other papers by E. Delmas in
Current site
Google Scholar
PubMed
Search for other papers by C. Gérard in
Current site
Google Scholar
PubMed
Search for other papers by E. Meugnier in
Current site
Google Scholar
PubMed
Search for other papers by A. Bravard in
Current site
Google Scholar
PubMed
Search for other papers by C. Pinteur in
Current site
Google Scholar
PubMed
Search for other papers by N. Vega in
Current site
Google Scholar
PubMed
Search for other papers by N. Bendridi in
Current site
Google Scholar
PubMed
Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France
Search for other papers by D. Cheillan in
Current site
Google Scholar
PubMed
Search for other papers by S. Fourati in
Current site
Google Scholar
PubMed
Search for other papers by D. Rainteau in
Current site
Google Scholar
PubMed
Search for other papers by M. Le Barz in
Current site
Google Scholar
PubMed
Search for other papers by S. Binda in
Current site
Google Scholar
PubMed
Search for other papers by F. Leulier in
Current site
Google Scholar
PubMed
Search for other papers by A. Bernalier-Donadille in
Current site
Google Scholar
PubMed
Search for other papers by H. Vidal in
Current site
Google Scholar
PubMed
Abstract
The implication of gut microbiota in the pathophysiology of type 2 diabetes, one of the major health concerns worldwide, has demonstrated the benefits of using probiotics to improve dysbiosis. Facing the lack of defined research strategy to found and qualify bacterial with real antidiabetic activity, we have developed a program to identify, select and validate novel strains able to improve metabolic alterations in type 2 diabetes. Among potential candidates, we identified Bacteroides faecichinchillae (named BAfa hereafter), and the present work presents the validation of the antidiabetic potential of the ST37 (DSMZ 26883) BAfa strain in mice fed a high-fat high-sucrose (HFS) diet for 10 weeks followed by 4 weeks of treatment. Daily gavage with live, but not heat inactivated, BAfa improved glucose tolerance, fasting hyperinsulinemia and liver triglyceride content in HFS fed mice. Furthermore, these beneficial effects were retained after lyophilization. Using this preclinical model, we characterised BAfa mechanism of action, showing that four weeks of treatment was associated with reduced hepatic accumulation of ceramides, key actors of insulin resistance. The underlying mechanism could be related to BAfa-induced changes in the intestinal bile acid profile and inhibition of the Fxr-Fgf15 pathway in the ileum. BAfa supplementation during 4 weeks in HFS fed mice was also associated with mild modifications of gut microbiota composition, with the upregulation of several species known for their beneficial metabolic actions (such as Lactobacillus johnsonii, Limosilactobacillus reutei, Roseburia, Turicimonas muris, Phocaeicola dorei or Akkermansia muciniphila) and for being up-regulated during metformin treatment. Altogether, these data indicate that BAfa and related B. faecichinchillae strains could be considered for developing next-generation probiotics to treat type 2 diabetes, potentially in combination with the anti-diabetic drug metformin.
| 全部期间 | 过去一年 | 过去30天 | |
|---|---|---|---|
| 摘要浏览次数 | 201 | 201 | 79 |
| 全文浏览次数 | 5 | 5 | 2 |
| PDF下载次数 | 15 | 15 | 6 |
